Compare · NVO vs ONCO
NVO vs ONCO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Onconetix Inc. (ONCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ONCO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 158175.0x ONCO ($1.2M).
- Over the past year, NVO is down 44.1% and ONCO is down 99.7% - NVO leads by 55.6 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for ONCO).
- NVO has more recent analyst coverage (25 ratings vs 0 for ONCO).
- Company
- Novo Nordisk A/S
- Onconetix Inc.
- Price
- $42.19+2.89%
- $0.94-7.83%
- Market cap
- $183.15B
- $1.2M
- 1M return
- -8.44%
- -74.85%
- 1Y return
- -44.09%
- -99.72%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 8
- 4
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest ONCO
- Realbotix Reports Financial Results for Q2-2026
- Onconetix Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
- Realbotix Provides Update on Nasdaq Listing
- Onconetix Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
- SEC Form 10-Q filed by Onconetix Inc.
- SEC Form EFFECT filed by Onconetix Inc.
- SEC Form EFFECT filed by Onconetix Inc.
- Amendment: SEC Form S-1/A filed by Onconetix Inc.